Abstract
Malaria and leishmaniasis are the most prevalent tropical diseases caused by protozoan parasites. Half of worlds population is at risk of malaria and more than 2 million of new cases of leishmaniasis occur annually. There are no vaccines available for these diseases and current treatments suffer from several limitations. Therefore, novel drugs for malaria and leishmaniasis are much-needed. This article reviews the agents currently in use for treatment of these diseases, their known mechanisms of action and weaknesses. We present an overview of the main strategies for drug discovery and the relevance of these parasites genomics/proteomics data for a rational search of molecular targets and matching leads. In this direction, we emphasize the importance of the highly integrated partnerships and networks between scientists in academic institutions and industry involving several countries that promise to increase the chances of success and enhance cost-effectiveness in drug discovery against these parasitic diseases. In addition, we approach the available assays for testing lead compounds in large scale and their limitations for they represent one of the bottlenecks in the pipeline for novel drug discovery. We conclude the article presenting a recent coordinated initiative (TDR Transfection Network) established to overcome some of these limitations by the generation of Plasmodium and Leishmania transgenic parasites better suited for HTS platforms.
Keywords: Leishmaniasis, malaria, chemotherapy, drug discovery, molecular targets
Current Drug Targets
Title: Current Treatment and Drug Discovery Against Leishmania spp. and Plasmodium spp.: A Review
Volume: 10 Issue: 3
Author(s): Angela Kaysel Cruz, Juliano Simoes de Toledo, Mofolusho Falade, Monica Cristina Terrao, Sumalee Kamchonwongpaisan, Dennis E. Kyle and Chairat Uthaipibull
Affiliation:
Keywords: Leishmaniasis, malaria, chemotherapy, drug discovery, molecular targets
Abstract: Malaria and leishmaniasis are the most prevalent tropical diseases caused by protozoan parasites. Half of worlds population is at risk of malaria and more than 2 million of new cases of leishmaniasis occur annually. There are no vaccines available for these diseases and current treatments suffer from several limitations. Therefore, novel drugs for malaria and leishmaniasis are much-needed. This article reviews the agents currently in use for treatment of these diseases, their known mechanisms of action and weaknesses. We present an overview of the main strategies for drug discovery and the relevance of these parasites genomics/proteomics data for a rational search of molecular targets and matching leads. In this direction, we emphasize the importance of the highly integrated partnerships and networks between scientists in academic institutions and industry involving several countries that promise to increase the chances of success and enhance cost-effectiveness in drug discovery against these parasitic diseases. In addition, we approach the available assays for testing lead compounds in large scale and their limitations for they represent one of the bottlenecks in the pipeline for novel drug discovery. We conclude the article presenting a recent coordinated initiative (TDR Transfection Network) established to overcome some of these limitations by the generation of Plasmodium and Leishmania transgenic parasites better suited for HTS platforms.
Export Options
About this article
Cite this article as:
Cruz Kaysel Angela, de Toledo Simoes Juliano, Falade Mofolusho, Terrao Cristina Monica, Kamchonwongpaisan Sumalee, Kyle E. Dennis and Uthaipibull Chairat, Current Treatment and Drug Discovery Against Leishmania spp. and Plasmodium spp.: A Review, Current Drug Targets 2009; 10 (3) . https://dx.doi.org/10.2174/138945009787581177
DOI https://dx.doi.org/10.2174/138945009787581177 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Endocrinological Aspects of Proteinuria and Podocytopathy in Diabetes: Role of the Aldosterone/Mineralocorticoid Receptor System
Current Diabetes Reviews Prorenin and the (Pro)renin Receptor in Retinal Pathology
Current Hypertension Reviews Exercise in Youth with Type 1 Diabetes
Current Pediatric Reviews The Effect of <i>Myrtus communis</i> Aqueous Extract-Containing Gel on Wound Healing in Streptozotocin-Induced Diabetic Rats
Current Drug Discovery Technologies Epigenetic Control of Hypertension by DNA Methylation: A Real Possibility
Current Pharmaceutical Design Evaluation and Management of Asymptomatic Bradyarrhythmias
Current Cardiology Reviews Perforated One Anastomosis Gastric Bypass, How we Managed and Review of Literature
New Emirates Medical Journal FoxO3a Governs Early Microglial Proliferation and Employs Mitochondrial Depolarization with Caspase 3, 8, and 9 Cleavage During Oxidant Induced Apoptosis
Current Neurovascular Research S-Nitrosylation: Targets, Controls and Outcomes
Current Genomics Clinical Pharmacology and Lesion Penetrating Properties of Second- and Third-Line Antituberculous Agents Used in the Management of Multidrug-Resistant (MDR) and Extensively-Drug Resistant (XDR) Tuberculosis
Current Clinical Pharmacology Glucocorticoid Excess Induces Accumulation of Cardiac Glycogen and Triglyceride: Suggested Role for AMPK
Current Pharmaceutical Design Current Status and Perspectives in Peptide Receptor Radiation Therapy
Current Pharmaceutical Design The Effects of Zataria Multiflora on Blood Glucose, Lipid Profile and Oxidative Stress Parameters in Adult Mice During Exposure to Bisphenol A
Cardiovascular & Hematological Disorders-Drug Targets Cardiac Metabolism in Myocardial Ischemia
Current Pharmaceutical Design In Vitro Data of Current Therapies for SARS-CoV-2
Current Medicinal Chemistry Oxaliplapin and Capecitabine (XELOX) Based Chemotherapy in the Treatment of Metastatic Colorectal Cancer: The Right Choice in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Application of Microdialysis in Clinical Pharmacology
Current Clinical Pharmacology Possible Roles of Reg Family Proteins in Pancreatic Islet Cell Growth
Endocrine, Metabolic & Immune Disorders - Drug Targets Lipid-Based Systems for Delivery of Biological Macromolecules
Recent Patents on Nanomedicine Herbal Drugs for Diabetic Treatment: An Updated Review of Patents
Recent Patents on Anti-Infective Drug Discovery